Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets.
Summary of "Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets."
Seeking to improve ovarian cancer therapy, we compared biological characteristics of the moderately-aggressive OVCAR-3 cell line with two highly aggressive ovarian cancer cell populations: the SK-OV-3 cell line, and HASCJ primary cells isolated from the ascitic fluid of a patient with FIGO stage IV ovarian cancer. Secretion of angiogenic factors was not discriminative, whereas cell invasion through Matrigel and vasculogenic mimicry were much greater in the more aggressive cells. Among 10 agents tested for their ability to decrease cancer cell aggressivity using these two models, inhibitors of Stat3, IGF-IR and Rho GTPase were found to be the most promising.
Affiliation
Laboratoire M.E.R.C.I - EA 3829, Faculté de Médecine et de Pharmacie, Université de Rouen, Rouen, France. caroline.gest@yahoo.fr
Journal Details
This article was published in the following journal.
Name: Cancer letters
ISSN: 1872-7980
Pages: 207-17
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22120672
- DOI: http://dx.doi.org/10.1016/j.canlet.2011.11.026
Medical and Biotech [MESH] Definitions
Stat3 Transcription Factor
A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-6 family members. STAT3 is constitutively activated in a variety of TUMORS and is a major downstream transducer for the CYTOKINE RECEPTOR GP130.
Fluorometry
An analytical method for detecting and measuring FLUORESCENCE in compounds or targets such as cells, proteins, or nucleotides, or targets previously labeled with FLUORESCENCE AGENTS.
Topotecan
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Ovarian Failure, Premature
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
Primary Ovarian Insufficiency
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
PubMed Articles
Ovarian cancers migrate and metastasize over the surface of the peritoneal cavity. Consequently, dysregulation of mechanisms that limit cell migration may be particularly important in the pathogenesis...
Effects of Siltuximab on the IL-6 Induced Signaling Pathway in Ovarian Cancer.
PURPOSE: To explore potential therapeutic strategies for interrupting the IL-6 signaling pathway, we measured IL-6 expression in ovarian cancer tissues, and evaluated the effects of a monoclonal anti-...
AIM: Signal transducer and activator of transcription 3 (STAT3) plays an important role in the tumor formation, prognosis and chemoresistance of ovarian cancer. Our goal was to investigate the effec...
Microtubule-targeted chemotherapeutic agents inhibit STAT3 signaling.
The transcription factor STAT3 is inappropriately activated in the majority of breast tumors, especially in aggressive and invasive ones. In addition to driving expression of genes promoting malignanc...
Increasing evidence in the past few years has shown that miRNAs could serve functionally as "oncogenes" or "tumor suppressor genes" and regulate multiple cellular processes relevant to carcinogenesis...
Clinical Trials
Ovarian cancer is most often recognized in advanced clinical state, the initial therapeutic strategies consist of a platinum containing chemotherapy subsequent to primary surgery. Although...
M. D. Anderson Symptom Inventory - Ovarian Cancer
The goal of this behavioral research study is to learn more about the kind of symptoms that ovarian cancer patients experience. The Primary Aim is to develop and validate an ovarian-cance...
Toremifene in Treating Patients With Ovarian Cancer
RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using toremifene may fight ovarian cancer by reducing the production of estrogen. PURPOSE: Randomized...
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen
Ovarian cancer has the highest mortality rate of gynecologic malignancies and the overall 5-year survival rate of ovarian cancer is only 20-30%. Additionally, the incidence of ovarian canc...
Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer
RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer. PURPOSE: This clinical trial is...
